Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited is a global pharmaceutical company headquartered in Tokyo, Japan, dedicated to the research, development, manufacturing, and sale of innovative pharmaceuticals. Its core mission is "To contribute to the enrichment of quality of life around the world" by addressing diverse medical needs.

The company's product portfolio primarily focuses on oncology and cardiovascular diseases, leveraging its expertise in antibody-drug conjugate (ADC) technologies. Key products include Enhertu (trastuzumab deruxtecan), a flagship oncology treatment for HER2-positive and HER2-low breast cancer, and Lixiana (edoxaban), an anticoagulant. Daiichi Sankyo also develops and provides other innovative pharmaceuticals, generic drugs, vaccines, and over-the-counter medicines.

Recent leadership changes include Hiroyuki Okuzawa, who will assume the role of Representative Director, President & CEO starting April 1, 2025, with Sunao Manabe serving as Executive Chairperson. Daiichi Sankyo recently postponed its annual report and five-year business plan announcement to May 11, 2026, citing the need to review supply plans for its oncology portfolio and development pipeline amidst rapidly changing business conditions, which led to a more than 10% drop in its shares. The company maintains a strong market position as a leader in the ADC space, with significant collaborations with AstraZeneca for Enhertu and Datroway, and with Merck & Co. for other ADC candidates.